Skip to main content
Publications
Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075
Ko DT, Khan AM, Kotrri G, Austin PC, Wijeysundera HC, Koh M, Chu A, Jackevicius CA, Lawler PR, Tu JV. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018 Nov 6;7(21):e010007. doi: 10.1161/JAHA.118.010007
Jeyakumar G, Tu JV, Austin PC, Hall R, Jin A, Manuel D, Silver FL, Swartz R, Chu A, Khan AM, Kapral MK. Rural-urban differences in stroke incidence, mortality and risk factor prevalence in Ontario. Poster presented at the American Heart Association/American Stroke Association 2017 International Stroke Conference; February 21, 2017. Houston, TX. [abstract] Stroke. 2017 Feb; 48(Suppl_1):180. doi: 10.1161/str.48.suppl_1.wp180